Ascenta Therapeutics

Ascenta Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to discovering and developing new medicines to stop cancer. Our core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. We have a compound in Phase IIb clinical trials that inhibit the Bcl-2 family of proteins (Bcl-2, Bcl-xL, Bcl-w, and Mcl-1) and a pipeline that targets IAP (inhibitors of apoptosis proteins) and HDM2 (inhibitor of the p53 tumor suppressor protein). Our development team has broad expertise in oncology and is focused exclusively on addressing the unique obstacles and complex challenges cancer brings to drug development. We are headquartered in Malvern, Pennsylvania in the greater Philadelphia area.